---
title: "Online MBCT for People with Multiple Sclerosis and Mild–Moderate Depression: Hybrid Trial Protocol"
id: "plos-one-22-online-mindfulness-based-cognitive-therapy-for-people-with-multiple-sclerosis"
canonical_url: "https://medichelpline.com/clinical-feed/plos-one-22-online-mindfulness-based-cognitive-therapy-for-people-with-multiple-sclerosis"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "PLOS ONE (Medicine)"
source_url: "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362553"
published_at: "2026-11-13T14:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Online MBCT for People with Multiple Sclerosis and Mild–Moderate Depression: Hybrid Trial Protocol
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/plos-one-22-online-mindfulness-based-cognitive-therapy-for-people-with-multiple-sclerosis
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** PLOS ONE (Medicine)
- **Source URL:** [Original Journal Publication](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362553)
- **Published At:** 2026-11-13T14:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The protocol describes a type 1 hybrid effectiveness–implementation study testing an online, tailored **mindfulness-based cognitive therapy** (**MBCT**) course for people with **multiple sclerosis** (PwMS) who have mild-to-moderate depression. - Study design is an embedded mixed-methods approach combining a powered waitlist randomized controlled trial (minimum N=152) with qualitative interviews and a process evaluation using RE-AIM informed by PRISM. - Primary clinical endpoint is change in depression measured continuously by **HADS-D**, assessed at baseline, immediately post-intervention (8 weeks), and at three-month follow-up (21 weeks). - The intervention is an 8-week live online group MBCT course (weekly 2.5-hour sessions, up to 15 participants) delivered by trained instructors experienced in MS care; home practice up to 45 minutes/day is included. - Eligibility requires adult age, neurologist-confirmed MS, English proficiency, BDI-II score 14–28 indicating mild-moderate depression, primary care registration, and Canadian residence; key exclusions include active suicidal ideation, psychosis, significant cognitive impairment (MoCA <26), recent MBCT (past 2 years), or life-limiting comorbidity. - Quantitative analysis plan uses linear mixed-effects models with group, time, and interaction terms; sample size calculation targets a between-group difference of ~2 HADS-D units (SD 3.5) with 80% power, accounting for clustering and 16% attrition. - Implementation outcomes will be collected over 12 months and reported with RE-AIM/PRISM; qualitative interviews (30–40 participants plus HCPs, instructors, decision makers) will explore acceptability, barriers, facilitators, and tailoring needs. - Recruitment sources include MS organizations, clinic networks, and social media; randomization occurs in clusters of 30 with 1:1 allocation to immediate MBCT or waitlist control. - The trial is registered on ClinicalTrials.Gov (Identifier: NCT07742579) and will be conducted online through the University of Toronto; data will be available after study completion per the authors. - The source did not report final results, effect sizes beyond planned assumptions, nor timelines for reporting beyond 12-month implementation assessment; these remain to be determined by trial completion.
## Clinical Analysis & Structured Key Points
Online mindfulness-based cognitive therapy for people with multiple sclerosis with mild-to-moderate depression– protocol for a type 1 hybrid effectiveness-implementation study | PLOS One Browse Subject Areas ? Click through the PLOS taxonomy to find articles in your field. For more information about PLOS Subject Areas, click here . Article Authors Metrics Comments Media Coverage Reader Comments Figures Figures Abstract Background Mindfulness-based cognitive therapy (MBCT) is an effective treatment for recurrent depression in the general population and is recommended in clinical guidelines for those with mild-moderate depression. However, the effectiveness of MBCT in people with multiple sclerosis (PwMS) with mild to moderate depression is unknown. Further, how best to tailor and implement MBCT for PwMS is largely unstudied. This manuscript describes the study protocol for a hybrid-effectiveness study to evaluate online MBCT tailored for PwMS. Methods This type 1 hybrid effectiveness-implementation study will employ an embedded mixed methods experimental design. Quantitative findings will be collected through a powered waitlist randomized controlled trial examining online MBCT in a minimum of 152 PwMS with case-ness of mild-moderate depression (Clinical Trials Gov #NCT07742579). The intervention will consist of an online 8-week MBCT course with weekly sessions conducted by qualified mindfulness instructors experienced int the care of PwMS. Questionnaires will be collected at baseline, post-intervention, and 3 months later. The primary outcome will be depression, measured using the Hospital Anxiety and Depression Score – Depression (HADS-D). An intention-to-treat analysis will be conducted. Qualitative findings will be collected through semi-structured interviews with 30–40 MBCT participants, HCPs, MBCT instructors, and MS decision makers. Thematic analyses will be used to analyze interview data. The RE-AIM PRISM tool will be used to evaluate implementation and mixed data assessed in a joint display. Conclusion The results from this study will provide evidence regarding the effectiveness of online MBCT in PwMS with mild to moderate depression, recommendations for intervention tailoring and implementation. Findings will be disseminated through traditional and novel, creative knowledge mobilization methods. Citation: Simpson R, Scandiffio J, Langer L, Munce S, Sureshkumar A, Feinstein A, et al. (2026) Online mindfulness-based cognitive therapy for people with multiple sclerosis with mild-to-moderate depression– protocol for a type 1 hybrid effectiveness-implementation study. PLoS One 21(11): e0362553. https://doi.org/10.1371/journal.pone.0362553 Editor: Jenna Scaramanga, PLOS: Public Library of Science, UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND Received: October 20, 2026; Accepted: October 23, 2026; Published: November 13, 2026 Copyright: © 2026 Simpson et al. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability: No datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion. Funding: This study is receiving funding from the National MS Society/MS Canada RFA (#1541284). The funder will have no role in the design, conduct, analysis, and reporting of the trial. Competing interests: RS’s research is supported by Physicians Services Incorporated, Associated Medical Services Healthcare, CIHR, and MS Canada. SM is the EIC of JMIR Rehabilitation and Assistive Technologies, PS has received honoraria as a speaker and member on advisory boards for EMD Serono, Novartis Pharmaceuticals, Roche Pharmaceuticals, Eli Lilly Canada, Sanofi Genzyme, and Amgen Pharmaceuticals. She is a co-investigator on research supported by MS Canada and CIHR. The other authors declare no competing interests. This does not alter our adherence to PLOS ONE policies on sharing data and materials. Introduction Multiple sclerosis (MS) is a highly disabling chronic inflammatory neurodegenerative condition which affects over 2,800,000 worldwide [ 1 ]. MS affects females at a higher rate than males, with females diagnosed at approximately a 3:1 ratio to males [ 2 ]. People living with multiple sclerosis (PwMS) rarely experience the condition as a stand-alone diagnosis. The most common comorbidity is depression which affects ~23.7–30.5% [ 3 , 4 ] PwMS and is typically chronic. The etiology of depression in PwMS is likely multifactorial, including genetic, immune-inflammatory, and psychosocial [ 5 ], however comorbid depression is commoner in those PwMS who are aged 42–57, have a secondary progressive phenotype, and are more physically disabled [ 6 ]. Comorbid depression strongly correlates positively with fatigue [ 7 ] and self-stigma [ 8 ], and negatively with self-efficacy and self-esteem [ 6 ]. Of added concern, those PwMS with comorbid depression are less likely to adhere to disease modifying therapies (DMTs) for MS [ 9 ], and more likely to engage in adverse health behaviours such as smoking and alcohol use [ 6 ]. Although comorbid depression exerts strong negative effects on quality of life (QoL) in PwMS [ 10 ], it is treatable. Limited evidence supports the use of pharmacological agents in the treatment of comorbid depression in PwMS; systematic reviews confirm that treatment attrition for antidepressants among PwMS with depression is very high in clinical trials [ 11 , 12 ]. However, in meta-analyses, both cognitive behavioural therapy (CBT) and Mindfulness-based interventions (MBIs) have been found to be effective in treating symptoms of depression and have low attrition in PwMS [ 13 – 15 ]. Furthermore, previous work has shown that PwMS express a preference for behavioural programming for managing mood [ 16 ]. Indeed, both CBT and MBIs appear to be acceptable to PwMS. To optimize effects, tailoring is required [ 17 , 18 ]. Despite this, depression in PwMS is undertreated [ 6 ]. Based on evidence from the general population, an intervention that incorporates elements of both CBT and MBIs is likely to have incremental benefits for PwMS with comorbid depression. Indeed, Mindfulness-Based Cognitive Therapy (MBCT) was developed and evidenced as a preventative treatment for depressive relapse [ 19 ], building on well-established evidence for Mindfulness-Based Stress Reduction (MBSR) as a treatment for stress in people with chronic medical conditions, and CBT. In the general population, MBCT is recommended in best practice guidelines for those with mild-moderate depression, whereas those with severe depression should have individualised treatment [ 20 ]. MBCT is typically delivered as a group and includes psychoeducation, cognitive and behavioural tasks designed to raise awareness of and address putative key drivers of depression such as ruminative cognition and negative affect [ 19 ]. Besides strong evidence of effectiveness for MBCT in decreasing symptoms and recurrence of depression in the general population [ 21 , 22 ], including self-stigma [ 23 ], it also improves positive mental health outcomes such as QoL [ 24 ], mindfulness, self-compassion [ 25 ], positive affect and spirituality [ 26 ]. Indeed, among PwMS, the largest pooled effects in meta-analyses of MBIs are for improving mental health-related QoL [ 15 ]. Positive effects from MBCT have been shown to be stable for up to 2 years post treatment in people with depression – this is important because for a self-management intervention for PwMS (a chronic, progressive condition) to have a meaningful impact, effects have to be longitudinal and ideally incremental, meaning that with the right infrastructure and support, skills continue to develop and endure over time [ 27 ]. There are well documented inequities related to mental health care access faced by PwMS [ 28 ]. Online delivery of self-management resources helps to address some of these inequities by improving access for those PwMS who are more physically disabled, of lower social means, and living rurally, and hybrid (live and asynchronous) digital self-management interventions are more effective for people with chronic neurological disorders than those fully digitized [ 29 ]. Indeed, qualitative research synthesis suggests PwMS prefer a hybrid of live (synchronous) and asynchronous MBI offerings, which maximize acceptability and accessibility, respectively [ 17 , 18 ]. Community, camaraderie and common humanity are suggested as key factors which motivate sustained participation in MBIs for PwMS [ 18 ]. Those studies which have demonstrated long-term benefits from MBCT have highlighted the importance of ongoing access to learning materials beyond the standard 8-week course [ 30 ], and that for those people with depression, learning to use mindfulness is a longitudinal process which involves increased self-awareness, perspective-taking and acceptance, and requires continued practice to exert agency [ 31 ]. Taken together, implemented at scale, MBCT has the potential to help a large number of PwMS. However, there is a lack of evidence regarding the effectiveness of MBCT in PwMS with mild-to-moderate depression and there is a lack of understanding as to how to effectively implement this intervention for PwMS. Objectives The overall aim of this project is to implement and evaluate online MBCT tailored for PwMS. Specific objectives include: Conduct a pragmatic, powered waitlist randomised controlled trial (RCT) of effectiveness of tailored online MBCT among PwMS who have case-ness of mild to moderate depression. Evaluate implementation of the tailored online MBCT course for PwMS who have mild to moderate depression using the RE-AIM framework, informed by PRISM, through a parallel process evaluation. Methods This type 1 hybrid effectiveness implementation study will employ mixed methods and comprises a powered RCT to evaluate the effectiveness of the tailored MBCT course, embedded qualitative interviews to explore participants’ experiences, and a process evaluation of the implementation of the course. Implementation will be examined using the RE-AIM (Reach, Effectiveness, Adoption, Implementation & Maintenance) framework, informed by PRISM (Practical, Robust Implementation and Sustainability Model), of participants in the course, and explores barriers and facilitators to implementation. This approach was chosen with the rationales of triangulation and expansion to examine convergence between quantitative and qualitative findings and to more comprehensively study the intervention, including factors influencing its use and implementation. This allows us to expand upon not only whether it is effective but also how the intervention is perceived and should be implemented. The trial was registered on ClinicalTrials.Gov (Identifier: NCT07742579) on July 31, 2026. The trial will be conducted online through the University of Toronto. This protocol follows the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) reporting guidelines for a RCT protocol. Eligibility Inclusion criteria will include: 1. Age > / = 18; 2. Neurologist confirmed MS diagnosis (McDonald criteria [ 32 ]); 3. Able to understand spoken and written English; 4. A score of 14–28 on the Beck Depression Inventory-II (BDI-II) signifying mild-moderate depression [ 33 ]; 5. Registered with a primary care provider (family physician or neurologist), 6. Residing in Canada. Exclusion criteria will include: 1. Potentially life-threatening comorbidities (suicidal ideation [i.e., score of 2 or 3 on the BDI-Fast Screen (BDI-FS) suicidal ideation question], history of psychosis, terminal/life threatening inter-current illness), or those such conditions expected to significantly limit participation and adherence (pregnancy, cognitive impairment, i.e., score <26 on the Montreal Cognitive Assessment – MoCA) [ 34 ], and 2. Receipt of MBCT in the past 2 years (completed at least 4/8 sessions). Recruitment and trial procedures Study materials (e.g., study flyer) will be disseminated by NeuroSask Active and Connected, MS Canada, the Canadian Network of MS Clinics, and social media (e.g., MS groups on Facebook). Potential participants can reach out to the study team to indicate their interest and will undergo eligibility screening. Initial contact between participants and the research study team will always be by telephone, or videoconferencing software, where baseline eligibility screening will take place ( Fig 1 ). Outstanding participant questions about the study can also be addressed at this point. Following this call, the research study team will send electronically a Participant Information Leaflet, consent forms, and baseline questionnaires to be completed via REDCap. Download: PNG larger image TIFF original image Fig 1. Participant timeline: schedule of enrollment, interventions, and assessments. https://doi.org/10.1371/journal.pone.0362553.g001 Randomization will be generated using a random computer-generated scheduler (e.g., SAS PROC PLAN) by a biostatistician who is unaware of participant identity and uploaded to REDCap software for the research coordinator to assign treatment allocation to recruited participants. As the design is a waitlist-controlled trial, randomization will be performed in clusters of 30 participants and will be allocated to Intervention or Waitlist Control arms in a 1:1 allocation in blocks of 2 ( Fig 2 ). A waitlist control was selected as the comparator because there is currently no standard of care intervention for PwMS who have mild-moderate depression. Our pragmatic study design will thus compare MBCT to the care PwMS in Canada actually receive and will thus allow assessment of incremental benefit rather than efficacy. Download: PNG larger image TIFF original image Fig 2. Participant Flow Chart. https://doi.org/10.1371/journal.pone.0362553.g002 Participant blinding in MBI research is challenging [ 35 ]. Pragmatic mitigation strategies in this study include [ 35 ]: 1) randomization will be generated via computerized randomization schedule generation and only the PI and statistician will have access to the schedule; 2) assessors and statistician blinded to group allocation for data entry, analysis, participant questionnaire data identifiable only by random study ID, group allocation concealed until final analysis; 3) publicly accessible study information kept general, no suggestion of intervention superiority; 4) participants advised only that they are allocated to an intervention ‘to improve emotional wellbeing’; 5) participants asked to not discuss group assignment with healthcare providers (HCPs) or study assessors for study duration. Intervention The intervention will comprise online group MBCT, tailored for PwMS, delivered live, via secure video conferencing software, by trained MBCT instructors, with up to 15 PwMS per group, weekly 2.5 hour sessions (with comfort breaks) for 8 weeks, including core meditation practices (mindful-breath, -body, -movement awareness), psychoeducation on depression, reflective group discussion (‘enquiry’), and home practices of up to 45 minutes/day [ 36 ]. Outcomes The primary outcome is change in depression, as measured by HADS-D as a continuous measure. Between and within group differences in HADS-D will be evaluated. Clinically significant reductions in HADS-D will also be examined as an exploratory outcome (a reduction of 20% considered a ‘minimally important difference’ [MID] [ 37 ]. Secondary outcomes will be collected for exploratory analysis and can be found in Table 1 . In all trial participants, trial outcomes will be collected remotely online using REDcap™, at baseline (T0), immediately post MBCT (T1), and 3 months later (T2) to assess magnitude and stability of treatment effects and/or hazards. Download: PNG larger image TIFF original image Table 1. Secondary outcomes analyzed. https://doi.org/10.1371/journal.pone.0362553.t001 Implementation outcomes will be collected throughout the study and formally assessed and reported following 12 months completion of the trial. These outcomes are described in Table 2 . Download: PNG larger image TIFF original image Table 2. Implementation outcomes analyzed. https://doi.org/10.1371/journal.pone.0362553.t002 Data collection Participants will be asked to fill out an online questionnaire at baseline (0 weeks), post-intervention (8 weeks) and follow-up (21 weeks). Online questionnaires will be used to collect data on the outcomes noted above and socio-demographic variables including age, sex, gender identity, race/ethnicity, current living situation, marital status, household income bracket, educational attainment, disease duration, disability level, number/type comorbid conditions, disease modifying therapy (DMT) and/or psychotropic use/type/dose. Further, a subset of participants (n = 30–40) will be invited to participate in one semi-structured interview via video-conferencing software examining motivations for participation, acceptability, accessibility, perceived effects of the MBCT program, as well as explore barriers and facilitators to implementation. HCPs, MBCT instructors and MS decision makers (e.g., clinic directors) will also be invited to participate in one semi-structured interview regarding their thoughts on the barriers and facilitators to implementation of MBCT for PwMS. Interview data will be digitally recorded and transcribed verbatim. Analysis The sample size was based on 3-month follow up data from Bogosian et al.[ 53 ] whereby, assuming the HADS-D scores are normally distributed, we expect to see a difference between the tailored online MBCT group and the usual care group of 2 units on average, with a standard deviation (SD) of 3.5, or a difference of 0.57 per SD. A minimum sample of 152 will provide a linear regression model with 3 time points (T0-T2) spaced at baseline (0 weeks), post-intervention (8 weeks) and follow-up (21 weeks) with 80% power. Sample size is adjusted for an assumed intracluster correlation of 0.2 of the repeated measures and assumed moderate baseline adjustment correction of 0.4 and 16% loss to follow-up for the analysis of our primary outcome, HADS-D based upon previous trial attrition rates. Sample size was calculated using SAS 9.4 for Windows (SAS Institute, North Carolina, USA). All statistical analyses will be undertaken by blinded staff (biostatistician). A statistical analysis plan will be completed and signed off prior to database lock. Demographic baseline characteristics will be summarized by allocated group using means and SDs for continuous variables if normally distributed and counts and percentages for categorical ones. Primary outcome of HADS-D will be analyzed comparing baseline, post-intervention and follow-up between study arms using a linear mixed effects model (LMM) with a group, time, and group by time interaction term. Secondary linear mixed models will be run adjusting for demographic baseline covariates following variable selection and shrinkage algorithm (i.e., LASSO) and compared to the unadjusted models. All covariates will be assessed for multicollinearity (tolerance statistic <0.4) and the most clinically relevant variable of correlated covariates will be included in the model. As there will be multiple iterations of tailored online group MBCT, within group dependencies may influence observed effects [ 54 ]. As such, subjects will be clustered within groups as random effect in LMM. Potential cluster effects [ 55 ] will be explored by examining between group means, and baseline-follow-up measures using one-way ANCOVA. Exploratory subgroup analyses on factors such as age, sex, gender identity, ethnicity will be undertaken and will also explore differential impact of MBCT between those with depression an
## Related Clinical Research

- [Autism and Menopause: Study Links Autism to More Severe Menopausal Symptoms](https://medichelpline.com/clinical-feed/medical-news-today-0-autism-is-linked-to-more-severe-menopause-symptoms-why.md)
- [ADHD medications lisdexamfetamine and atomoxetine show promise for perimenopausal brain fog](https://medichelpline.com/clinical-feed/medical-news-today-1-2-adhd-medications-show-early-promise-for-perimenopause-focus.md)
- [Neurological involvement in localized scleroderma: clinical features and neuroimaging patterns](https://medichelpline.com/clinical-feed/frontiers-in-immunology-9-neurological-involvement-in-localized-scleroderma-a-systematic-review-of.md)
- [Impact of Music-Based Therapies on Rehabilitation in Multiple Sclerosis: A Systematic Review](https://medichelpline.com/clinical-feed/bmj-open-9-potential-benefits-of-music-based-therapies-on-rehabilitation-outcomes-in.md)
- [Machine learning prediction of pain intensity in low back pain: Random Forest vs XGBoost with lumb](https://medichelpline.com/clinical-feed/plos-one-1-prediction-of-factors-contributing-to-pain-intensity-among-low-back-pain.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.